Analysis of therapeutic efficacy of chemoendocrine therapy for advanced prostate cancer using DNA microaray method

DNA微阵列法分析晚期前列腺癌化疗内分泌治疗的疗效

• 批准号: 15591679
• 负责人: TAKAHASHI Yoshito
• 金额: $ 1.86万
• 依托单位: Gifu University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2003
• 资助国家: 日本
• 起止时间: 2003 至 2004
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-15591679/
• 关键词: prostate cancer; hormone refractory; mRNA; molecular diagnosis; RT-PCR; 5-FU; TS; DPD; DNAマイクロアレイ; 治療効果; ホルモン治療

Recently the number of prostate cancer is progressed. The main therapy for advanced prostate cancer is endocrine therapy and/or chemotherapy, however, the therapeutic effect of more than half of advanced cancer has changed the low response after three years later.Thymidine synthase (TS) and Dihydropyridine dehydrogenase (DPD) was reported that the activity of those enzymes was progressed in relapsed cancer or hormone resistant cancer. At this time, we examined the appearance of TS and DPD in prostate cancer tissue using molecular diagnosis method such as RT-PCR. The titier of appearance of those enzymes in BPH tissue was superior to that in prostate cancer tissue. Our result was different from former reported article. Further examination among more number cases and long duration should be needed.

近年来前列腺癌的数量不断增加。晚期前列腺癌的主要治疗方法是内分泌治疗和/或化疗，然而，超过一半的晚期癌症的治疗效果在三年后改变了低反应。据报道，胸苷合成酶（TS）和二氢吡啶脱氢酶（DPD）的活性在复发的癌症或激素抵抗的癌症中有所提高。此时，我们采用RT-PCR等分子诊断方法检测前列腺癌组织中TS和DPD的形态。这些酶在前列腺增生组织中的表现明显优于前列腺癌组织。我们的结果与以往的报道不同。需要对更多病例和更长的时间进行进一步检查。